Verified Nov 2026
Other
·

Basel, Basel-Stadt
·
Since 1886
Sandoz, headquartered in Basel, Switzerland, manufactures generic medicines and biosimilars for global pharmaceutical markets. Founded in 1886, the company operates with 10,000–50,000 employees and generates over $10 billion in annual revenue. After spinning off from Novartis in 2023, Sandoz became an independent public company serving approximately 500 million patients across 100+ countries, delivering nearly 900 million treatments annually through a portfolio of 1,300–1,500 products.
Sandoz at a glance
Revenue
$10B+
Est. band
Employees
10,000-50,000
Founded
1886
Headquarters
Basel, Basel-Stadt
Import activity
6013
Industries
Automotive
Electric Vehicles
Medical
Industrial Equipment
Sourcing and import activity
From US customs bill-of-lading records
US sea imports
6013
Named foreign suppliers
50
Top origins
Germany · Belgium · India · China

Shared foreign counterparties do not establish that these companies buy from Sandoz.
What this tells a buyer
Customs records document 6,013 shipments, with primary manufacturing sources in Austria, Slovenia, India, and China, drawing supplies from 21 countries including Germany, Belgium, Italy, and Mexico.
The company produces generics representing 75% of sales and biosimilars comprising 25%, with recent announcements indicating expansion of its biosimilar pipeline and development of recombinant protein therapies.
In mid-2026, Sandoz committed an additional €150 million to its biopharmaceutical manufacturing facility in Toulouse, and signed a landmark agreement with Evotec covering up to 10 biosimilar molecules with potential payments exceeding $650 million.
Source: US customs bill-of-lading records and public filings · Last verified Nov 13, 2026
STABILITY SIGNALS
Established & active
140 years in operation (founded 1886).
6,013 US import shipments on record.
Overview
Sandoz, headquartered in Basel, Switzerland, manufactures generic medicines and biosimilars for global pharmaceutical markets. Founded in 1886, the company operates with 10,000–50,000 employees and generates over $10 billion in annual revenue. After spinning off from Novartis in 2023, Sandoz became an independent public company serving approximately 500 million patients across 100+ countries, delivering nearly 900 million treatments annually through a portfolio of 1,300–1,500 products.
At a glance
Attribute | Detail |
|---|---|
Founded | 1886 |
Headquarters | Basel, Basel-Stadt |
Employees | 10,000-50,000 |
Revenue | $10B+ (estimated) |
What Sandoz makes
The company produces generics representing 75% of sales and biosimilars comprising 25%, with recent announcements indicating expansion of its biosimilar pipeline and development of recombinant protein therapies.
Products and capabilities described on the company's own site include Steel (source: sandoz.com).
Trade and customs footprint
Customs records document 6,013 shipments, with primary manufacturing sources in Austria, Slovenia, India, and China, drawing supplies from 21 countries including Germany, Belgium, Italy, and Mexico. US customs bill-of-lading records list 6013 inbound shipments across 50 foreign suppliers, with top origins including Germany · Belgium · India · China.
Latest developments
2026-09-08 — Sandoz bets big on biosimilars, aims to double group sales ... (reuters.com)
2026-06-01 — Sandoz va investir 150 millions d’euros supplémentaires dans son site toulousain (lejournaldesentreprises.com)
2026-06-01 — Sommet Choose France : le Suisse Sandoz annonce 150 M€ d’investissement pour son site de biomédicaments de Toulouse - ladepeche.fr (ladepeche.fr)
2025-11-04 — In a landmark industry transaction, Evotec signs agreement with Sandoz, resulting in payments potentially over US$ 650 m plus royalties on portfolio of up to 10 biosimilar molecules - Evotec (evotec.com)
2025-08-27 — Sandoz welcomes Quebec government support for Boucherville plant modernization project | Canada: Corporate Site (sandoz.ca)
2025-08-12 — Elawan Energy signs renewable Power Purchase Agreement (PPA) with Sandoz to drive the energy transition in Europe – Elawan Energy (elawan.com)
Company details
In mid-2026, Sandoz committed an additional €150 million to its biopharmaceutical manufacturing facility in Toulouse, and signed a landmark agreement with Evotec covering up to 10 biosimilar molecules with potential payments exceeding $650 million. Sandoz was founded in 1886, has an estimated 10,000-50,000 employees, and is headquartered in Basel, Basel-Stadt. On the LightSource stability read it is rated "Established & active": 140 years in operation (founded 1886). 6,013 US import shipments on record.
Frequently asked questions
What does Sandoz do?
Sandoz, headquartered in Basel, Switzerland, manufactures generic medicines and biosimilars for global pharmaceutical markets. Founded in 1886, the company operates with 10,000–50,000 employees and generates over $10 billion in annual revenue. After spinning off from Novartis in 2023, Sandoz became an independent public company serving approximately 500 million patients across 100+ countries, delivering nearly 900 million treatments annually through a portfolio of 1,300–1,500 products.
Where is Sandoz headquartered?
Sandoz is headquartered in Basel, Basel-Stadt.
When was Sandoz founded?
Sandoz was founded in 1886.
How big is Sandoz?
Sandoz has an estimated 10,000-50,000 employees, with revenue in the $10B+ range (estimated).
Does Sandoz import from overseas suppliers?
US customs bill-of-lading records show 6013 inbound shipments for Sandoz, with top origins including Germany · Belgium · India · China.
Related suppliers
Explore other suppliers in the LightSource directory:
Last verified Nov 2026. Is this your company? Request a correction.
Location & contact
Evaluating suppliers like these?
This profile is part of a public-data sample of the full LightSource directory. Book a demo to see the full LightSource marketplace and supplier discovery platform — 1M+ credible suppliers, with AI-run sourcing events.
